Quarterly report [Sections 13 or 15(d)]

Condensed Statements of Operations (Unaudited)

v3.26.1
Condensed Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Income Statement [Abstract]    
Revenues
Operating Expenses:    
Research and development 413,000 1,099,000
Selling, general and administrative 2,435,000 833,000
Loss from Operations (2,848,000) (1,932,000)
Other Income (Expense)    
Interest income 67,000 32,000
Interest expense (63,000)
Change in fair value of warrant liability 11,000 126,000
Gain on settlement of vendor payable 998,000
Total Other Income, net 15,000 1,156,000
Net Loss (2,833,000) (776,000)
Dividend on preferred stock (103,000)
Deemed dividend (433,000)
Net Loss attributable to common stockholders’ $ (3,369,000) $ (776,000)
Net Loss Per Share - Basic $ (0.11) $ (0.33)
Net Loss Per Share - Diluted $ (0.11) $ (0.33)
Weighted average common shares outstanding - basic 30,283,031 2,345,087
Weighted average common shares outstanding - diluted 30,283,031 2,345,087